Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the appointment of Dr. Richard Mountfield as Vice-President of Global Regulatory Affairs, effective February 3rd , 2016. 

Richard is a pharmaceutical professional with extensive Regulatory Affairs (preclinical, clinical, registration, and post-marketing) & Drug Development experience including leadership, management and project roles. Prior to joining Celyad he held positions in Europe and the US for a number of top 20 Pharmaceutical companies (Novo Nordisk, Roche, Boehringer Ingelheim and Novartis). He has been responsible for global regulatory strategy and submissions across a number of therapeutic areas. Most recently he was the global regulatory lead responsible for developing and implementing approvable strategies for a large multi-indication oncology program within Novartis. Richard holds a PhD in Biochemistry from Aberystwyth University. 

Dr. Christian Homsy, CEO of Celyad: “We are pleased to welcome Richard to our executive management team, where he brings over 20 years of expertise in the field of regulatory affairs and drug development. Based on his experience in planning for Phase II and Phase III registration studies and indication expansion, Richard will drive the implementation of approvable global regulatory strategies for our clinical programs in cardiovascular diseases and in immuno-oncology “. 

Dr. Richard Mountfield: “I am very excited to be joining Celyad; a company at the forefront of using cell technology to improve patients’ lives in two therapeutic areas with huge unmet medical needs –oncology and cardiology. I am impressed with both the quality of the company and its leadership team and I look forward to contributing to its growth as a global player in oncology and cardiology”. 

Richard will be based in Boston, Massachusetts USA and will report directly to Christian Homsy, Chief Executive Officer. 

Download press release(s)

Press release

297.80 Ko

Communiqué de presse

311.93 Ko


268.95 Ko

Joint-PR-Invetech and Celyad SA Announce Collaboration to Realize the Commercial cGMP Prod...

Next News

Joint-PR-Invetech and Celyad SA Announce Collaboration to Realize the Commercial cGMP Prod...